Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
15 2월 2024 - 6:05AM
Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the
"Company"), an eyecare technology company focused on developing and
commercializing innovative, interventional technologies intended to
transform care and improve patients' lives, today announced the
launch of the Ergo-Series of the OMNI® Surgical System in Europe, a
technology that facilitates surgeons’ ability to perform minimally
invasive, implant-free glaucoma procedures in adults with
open-angle glaucoma.
The Ergo-Series was originally launched in the
United States in March 2023, and since has been broadly adopted by
surgeon users of OMNI due to its improved ergonomics and an
optimized cannula tip that provides gentle and precise access to
Schlemm’s canal. "We are pleased with all the positive feedback on
the OMNI Ergo-Series from surgeons in the United States, and we are
delighted to have now received CE Mark under the new EU Medical
Device Regulation to market this enhanced version of our OMNI
technology in Europe as well," said Paul Badawi, Co-Founder and
Chief Executive Officer of Sight Sciences. "We believe the improved
handle ergonomics, simplified viscoelastic preparation, and new
cannula tip design will be invaluable to our European partners, so
we are excited to launch the technology at the European Society of
Cataract and Refractive Surgeons (“ESCRS”) Winter meeting this week
in Frankfurt."
Professor Fritz Hengerer, Chief Medical Officer
and Director Bürgerhospital Eye Clinic in Frankfurt, said, “I
am particularly impressed with the improved ergonomics and overall
design enhancements of the OMNI Ergo-Series. These upgrades make
the OMNI Surgical System even more user-friendly which could
encourage surgeons to intervene earlier, when appropriate, to help
delay disease progression, thus helping to preserve vision and
potentially reduce the medication burden of patients with
glaucoma.”
“The previous iteration of the OMNI Surgical
System was seamlessly incorporated into my practice,” commented Dr.
Andrew Tatham, Consultant Ophthalmic Surgeon at Princess Alexandra
Eye Pavilion in Edinburgh and NHS Research Scotland Clinical Lead
for Ophthalmology. “The innovations in design of the Ergo-Series
have the benefit of making the device even more intuitive to hold
and operate. The enhanced cannula tip can provide gentle, precise
access to Schlemm’s canal and improved tactile feedback, giving the
surgeon confidence at every step of the procedure. I believe these
improvements make OMNI even more accessible for surgeons treating
all stages of open-angle glaucoma.”
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional technologies intended
to transform care and improve patients' lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world's most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company's OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and the cutting of trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world's leading cause of irreversible blindness. The Company's
TearCare® System technology is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”) when used in conjunction with manual expression
of the meibomian glands, enabling clearance of gland obstructions
by physicians to address the leading cause of dry eye disease. The
Company's SION® Surgical Instrument is a manually operated device
available in the United States to be used in ophthalmic surgical
procedures to excise trabecular meshwork.
For more information,
visit http://www.sightsciences.com.
Sight Sciences and TearCare are trademarks of
Sight Sciences registered in the United States. OMNI, OMNI ERGO,
and SION are trademarks of Sight Sciences registered in the United
States, European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Forward-Looking StatementsThis
press release, together with other statements and information
publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The Company intends
such forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with such safe harbor
provisions. Any statements made in this press release or during the
earnings call that are not statements of historical fact, including
statements about our beliefs and expectations, are forward-looking
statements and should be evaluated as such. Forward-looking
statements include, but are not limited to, statements concerning
the potential clinical and design benefits of the Ergo Series of
the OMNI Surgical System and their potential impact on clinical
decision-making; and anticipated launch dates for the Ergo-Series.
These statements often include words such as "anticipate,"
"expect," “suggests,” “plan,” “believe,” “intend,” “estimates,”
“targets,” “projects,” “should,” “could,” “would,” “may,” “will,”
“forecast” and other similar expressions. We base these
forward-looking statements on our current expectations, plans and
assumptions we have made in light of our experience in the
industry, as well as our perceptions of historical trends, current
conditions, expected future developments and other factors we
believe are appropriate under the circumstances at such time.
Although we believe these forward-looking statements are based on
reasonable assumptions at the time they are made, you should be
aware that many factors could affect our business, results of
operations and financial condition and could cause actual results
to differ materially from those expressed in the forward-looking
statements. These statements are not guarantees of future
performance or results. These forward-looking statements are
subject to and involve numerous risks, uncertainties and
assumptions, including those discussed under the caption “Risk
Factors” in our filings with the U.S. Securities and Exchange
Commission, as may be updated from time to time in subsequent
filings, and you should not place undue reliance on these
statements. These cautionary statements are made only as of the
date of this press release. We undertake no obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
Media
contact:pr@SightSciences.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@SightSciences.com
Sight Sciences (NASDAQ:SGHT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Sight Sciences (NASDAQ:SGHT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024